Table 1 Baseline characteristics of patients with anti-HMGCR myopathy (N = 55)
n (%) or median (range) | |
|---|---|
Sex, male/female | 30/25 |
Age at diagnosis, median (range), years | 67.7 (44–86.1) |
Prior statin use, n (%) | 55 (100) |
Atorvastatin use, n (%) | 46 (84) |
Diabetes mellitus, n (%) | 39 (72) |
Cardiovascular disease, n (%)* | 29 (53) |
Cancer within 3 years of diagnosis, n | 0 |
First serum CK levels at presentation, median (range), UI/L | 2935 (500–19,465) |
CK levels at treatment initiation, median (range), UI/L | 5000 (554–23,000) |
Myalgias, n (%) | 21 (38) |
Subjective oropharyngeal dysphagia, n (%) | 16 (29) |
Objective oropharyngeal dysphagia, n (%) | 5 (9) |
Proximal muscle weakness at presentation, n (%) | 33 (60) |
Proximal muscle weakness at treatment initiation, n (%) | 46 (84) |
Muscle biopsy, n (%) | 54 (98) |
Necrosis and regeneration, n (%) | 48 (87) |
Isolated sarcolemmal/capillary MAC deposition, n (%) | 4 (7) |
Regeneration only, n (%) | 1 (2) |
Normal, n (%) | 1 (1) |
Other abnormalities | |
MHC-1 expression on non-necrotic muscle fibers, n (%) | 26/51 (51) |
Sarcolemmal and/or capillary MAC deposition, n (%)** | 38/42 (90) |